In partnership with

EMBL logo

HCEMM-SU Thrombosis and Hemostasis Research Group

Group Description

Group Leader: Nikolett Wohner MD


Our research focuses on translational medicine in the field of thrombosis and hemostasis. Thrombi are complex structures that cannot be investigated in simplified systems, as red blood cells, leukocytes, platelets and molecules originating from these cells profoundly determine thrombus formation and
thrombolysis. In our studies we use in vitro, ex vivo and in vivo methods combined with advanced
microscopic technics to uncover the pathophysiology of hemostatic processes. We concentrate on the role of neutrophil extracellular traps, von Willebrand factor and the interaction thereof. Furthermore, we aim to shed light on the pathomechanism of bleeding or thrombotic complications in hematological diseases. Our results may thoroughly affect the development of new thrombolytic therapies and help to
identify new thrombotic markers.

2019

  1. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory
    multiple myeloma patients. Lovas S, Varga G, Farkas P, Masszi T, Wohner N, Bereczki Á, Adamkovich N, Borbényi Z, Szomor Á, Alizadeh H, Szaleczky E, Wolf K, Schneider T, Plander M, Szendrei T, Csacsovszki O, Csukly Z, Rajnics P, Egyed M, Nagy Z, Rejtő L, Illés Á, Mikala G, Váróczy L.  Int J Hematol. 2019 Nov;110(5):559-565. doi: 10.1007/s12185-019-02715-w. Epub 2019 Aug 7.

2018

  1. Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature.
    Varga G, Mikala G, Gopcsa L, Csukly Z, Kollai S, Balázs G, Botond T, Wohner N, Horváth L,
    Szombath G, Farkas P, Masszi T.
    J Oncol. 2018 Apr 23;2018:3970169. doi: 10.1155/2018/3970169. Review.
  1. Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor.
    Wohner N, Muczynski V, Mohamadi A, Legendre P, Proulle V, Aymé G, Christophe OD, Lenting PJ, Denis
    CV, Casari C.
    2018 Apr;103(4):728-737. doi: 10.3324/haematol.2017.175216

2017

  1. Thalidomide therapy in relapsed diffuse large B-cell lymphoma in elderly patients. Three cases. Wohner N, Varga G, Szloboda P, Farkas P, Masszi A, Horváth L, Szombath G, Várkonyi J, Benedek S, Masszi
    Orv Hetil. 2017 Oct;158(41):1642-1648. doi: 10.1556/650.2017.30873.

2016

  1. LDL receptor-related protein 1 contributes to the clearance of the activated factor VII-antithrombin complex. Fazavana JG, Muczynski V, Proulle V, Wohner N, Christophe OD, Lenting PJ, Denis CV.
    J Thromb Haemost. 2016 Dec;14(12):2458-2470. doi: 10.1111/jth.13502.

2015

  1. Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance. Wohner N, Legendre P, Casari C, Christophe OD, Lenting PJ, Denis CV. J Thromb Haemost. 2015 Feb 28. doi: 10.1111/jth.12885.
  1. Ultrastructure and composition of thrombi in coronary and peripheral artery disease: Correlations with clinical  and laboratory findings. Kovács A, Sótonyi P, Nagy AI, Tenekedjiev K, Wohner N, Komorowicz E, Kovács E, Nikolova N, Szabó L, Kovalszky I, Machovich R, Szelid Z, Becker D, Merkely B, Kolev K.
    Thromb Res. 2015 Feb 9. pii: S0049-3848(15)00059-6.

2014

  1. Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic
    thrombocytopenic purpura in mice. Morioka Y, Casari C, Wohner N, Cho S, Kurata S, Kitano A, Christophe OD, Lenting PJ, Li R, Denis CV, Prévost N. Blood. 2014 May 22;123(21):3344-53.

2013

  1. Clearance of von Willebrand factor. Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV.J Thromb Haemost. 2013 Jun;11 Suppl 1:202-11. doi: 10.1111/jth.12226. Review.
  1. On the versatility of von Willebrand factor. Rauch A, Wohner N, Christophe OD, Denis CV, Susen S, Lenting PJ.Mediterr J Hematol Infect Dis. 2013 Jul 10;5(1):e2013046.
  1. Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target, Peter J. Lenting, Cécile V. Denis and Nikolett Wohner Current Vascular Pharmacology 2013 Jul;11(4):448-56. Review.

2012

  1. Modulation of the von Willebrand factor-dependent platelet adhesion through alternative proteolytic pathways Wohner N, Kovács A, Machovich R, Kolev K Thromb Res. 2012 Apr;129(4):e41-6.

2011

  1. Lytic Resistance of Fibrin-Containing Red Blood Cells Wohner N, Sótonyi P, Machovich R, Szabó L, Tenekedjiev K, Silva MM, Longstaff C, Kolev K Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2306-13.

2010

  1. Neutrophil granulocyte-dependent proteolysis enhances platelet adhesion to the arterial wall under high-shear flow Wohner N, Keresztes Z, Sótonyi P, Szabó L, Komorowicz E, Machovich R, Kolev K J Thromb Haemost. 2010 Jul;8(7):1624-31.

2008

  1. Role of cellular elements in thrombus formation and dissolution. Wohner N. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):224-8
  2. Matrix metalloproteinases in the pathomechanism of stroke Recent advances and new strategies in stroke research Krasimir Kolev, Nikolett Wohner Editors: Zoltán Nagy, Franciska Erdő
This website uses cookies. For more information visit the Cookies & Privacy Policy page.